小细胞肺癌患者化疗后的药学监护

Pharmaceutical Care for a Patient with SCLC Postchemotherapy

目的:探讨临床药师如何实施药学监护。方法:以一位小细胞肺癌化疗后的患者为例,临床药师介入临床,参与药物治疗方案的制订,分析患者所用化疗药物、抗菌药、降血钙药物以及升血小板药物的综合应用,并对患者的治疗过程进行跟踪监测,对药物治疗效果及不良反应进行综合评估。结果:在临床医师的治疗及临床药师的药学监护下,患者的各项指标(化疗后的中性粒细胞比例、WBC计数、T、Plt等)趋于正常,可继续完成化疗疗程。结论:临床药师的介入使药物治疗更趋合理,在达到治疗目标的同时,减少了药物的不良反应,有利于提高临床的药物治疗水平。

Objective： To explore how to carry out pharmaceutical care. Method： Clinical pharmacists involved in such clinical drug therapy as making medication schedule, analyzing and evaluating the drugs used in a patient with SCLC after chemotherapy （ ineluding chemotherapeutics, antibiotics, hypocaleemie drugs and elevating platelet drugs, ere） , and conducting a comprehensive drug treatment assessment （including effectiveness and adverse reactions） in the whole therapy process. Result： By means of the treatment of clinicians and pharmaceutical care of clinical pharmacists, the biochemical indices of the patient （ such as proportion of neutrophils after chemotherapy, WBC count, body temperature, Plt, etc. ） tended to be normal, and the patient could support a further course of chemotherapy. Conclusion： The participation of clinical pharmacists can improve the rationality of drug treatment with fewer adverse reactions, which is benefit for the level of clinical drug treatment.